GlassScriptPhysician profile
Paul Neustein
NPI 1578529731
$6,329.91
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,356 · 2020: $656 · 2021: $1,814 · 2022: $1,103 · 2023: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,590.73 | 2019-2020 | |
| Astellas Pharma US INC | $740.64 | 2019-2022 | |
| Allergan, INC. | $541.80 | 2019-2022 | |
| Abbvie INC. | $465.12 | 2019-2023 | |
| Teleflex LLC | $412.85 | 2021-2023 | Urolift |
| Boston Scientific Corporation | $247.44 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $233.51 | 2020-2023 | Prolaris |
| Endo Pharmaceuticals INC. | $217.27 | 2019-2022 | |
| Axonics, INC. | $215.68 | 2021-2023 | Axonics |
| Myovant Sciences INC. | $196.29 | 2021-2022 | |
| Urogen Pharma, INC. | $187.29 | 2021-2022 | |
| Hollister Incorporated | $158.08 | 2020-2021 | |
| Pfizer INC. | $150.55 | 2019-2022 | |
| Urovant Sciences INC | $138.36 | 2021-2022 | |
| Medtronic, INC. | $114.09 | 2021-2023 | Interstim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $113.55 | 2021-2023 | |
| Coloplast Corp | $111.83 | 2019-2021 | |
| Janssen Biotech, INC. | $98.56 | 2020-2022 | |
| Amgen INC. | $70.90 | 2020-2022 | |
| Telix Pharmaceuticals | $59.12 | 2022-2023 | Illuccix |
| Merck Sharp & Dohme LLC | $45.91 | 2020-2021 | |
| Antares Pharma, INC. | $45.08 | 2021 | |
| Medtronic USA, INC. | $29.13 | 2020 | |
| Ferring Pharmaceuticals INC. | $27.01 | 2019 | |
| Convatec INC. | $22.43 | 2023 | |
| Travere Therapeutics, INC. | $21.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.07 | 2022 | |
| Accord Healthcare, INC. | $21.02 | 2022 | |
| Sagent Pharmaceuticals | $19.06 | 2022 | |
| Bard Access Systems, INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Neustein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.